Supporting HER2+ mBC Patients in Later Lines: AE Management and the Role of the Multidisciplinary Team
Experts discuss treatment options for HER2-positive metastatic breast cancer following progression on trastuzumab deruxtecan (T-DXd), weighing real-world data on tucatinib-capecitabine-trastuzumab versus T-DM1, considering factors such as resistance mechanisms, administration preferences, and side effect management.
Video content above is prompted by the following:
- What real world data following the use of Tucatinib and T-DXd that can help assist medical professionals.
Recent Videos
Related Content
